Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352303 | 0.88 | MEN1 (0.43) | CYP2D6CYP2C19TSHRMEN1GAA | |
| SCHEMBL6649699 | 0.78 | PKM (0.39) | CYP2D6CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL2460635 | 0.77 | CYP2D6 (0.52) | CYP2D6CYP2C19TSHR | |
| SCHEMBL838330 | 0.77 | CYP2D6 (0.37) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL2556795 | 0.77 | CYP2D6 (0.37) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL22076985 | 0.77 | CYP2D6 (0.37) | CYP2D6CYP2C19MEN1GAAKMT2A | |
| SCHEMBL29774458 | 0.76 | MEN1 (0.57) | CYP2D6MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL13268513 | 0.75 | — | — | |
| SCHEMBL1923786 | 0.75 | — | — | |
| SCHEMBL13268506 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593461-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1562928-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050101641-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | disclosed |
| US-6890928-B2 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040110805-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-06-10 | — | — | US | disclosed |
| WO-2004043943-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385836-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2002092588-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110805-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | CYP2D6 2990/4885CYP2C19 2425/4885TSHR 3809/4885 |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | CYP2D6 524/4885CYP2C19 1940/4885TSHR 2080/4885 |
| US-20050101641-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP3, MMP7 | CYP2D6 2940/4885CYP2C19 2215/4885TSHR 3876/4885 |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP2D6 2378/4885CYP2C19 2839/4885TSHR 4346/4885 |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | CYP2D6 3058/4885CYP2C19 2392/4885TSHR 3623/4885 |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | CYP2D6 3058/4885CYP2C19 2392/4885TSHR 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.